The firm's lead candidate, EN-374 for X-linked chronic granulomatous disease, is being evaluated in a Phase I/II trial.

Advanced ER-positive breast cancer patients on giredestrant and Afinitor had better progression-free survival versus standard therapy in the evERA trial.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

The firm has randomized participants in the REGENERATE-PD study of AB-1005 in the UK and Poland, with plans to expand to Germany next.

Regulators in the UK also approved the IDH1/2 inhibitor last week, making it the first precision targeted treatment in Europe for this post-surgery setting.

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm, which so far has focused on cancer, expects to file an IND application for a treatment for tyrosinemia type I and alkaptonuria next year.

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.